# The Placenta as a Target Organ for Poly- and Perfluoroalkyl Substances (PFASs): Molecular Mechanisms of Toxicity

**Authors:** Paola Inés Ingaramo, Maria Laura Zenclussen

PMC · DOI: 10.3390/ijms27042036 · International Journal of Molecular Sciences · 2026-02-22

## TL;DR

This paper reviews how exposure to PFAS chemicals affects the placenta and may harm pregnancy and fetal development.

## Contribution

The paper provides a comprehensive review of molecular mechanisms linking PFAS exposure to placental toxicity.

## Key findings

- PFAS exposure is associated with altered placental function and molecular pathways.
- Mixtures of PFASs complicate exposure analysis and health risk assessment.
- Current methodologies are being explored to evaluate PFAS mixtures in real-life scenarios.

## Abstract

Exposure to poly- and perfluoroalkyl substances (PFASs) has been a cause for concern for decades due to evidence linking exposure to these substances with adverse health effects. Its widespread use in industrial and consumer products combined with their persistence in the environment poses a toxicological and regulatory challenge. Due to its ubiquity, resistance to degradation, and accumulation in biological systems, humans are exposed to a mixture of multiple PFASs, which complicates the analysis of exposure effects. As PFASs pose a risk to human health, it is crucial to study their impact during vulnerable periods, such as pregnancy. In this regard, understanding the impact of PFASs on the placenta is essential, as they can affect both pregnancy and the well-being of the developing fetus. This article reviews the current evidence linking PFAS exposure with altered placental function, focusing on the affected molecular pathways. Furthermore, we examine current methodologies for analyzing the effects of exposure to complex mixtures and explore how these approaches could be employed to evaluate the potential impact of such mixtures on placental function in the context of real-life exposure to these chemicals.

## Full-text entities

- **Genes:** GPER1 (G protein-coupled estrogen receptor 1) [NCBI Gene 2852] {aka CEPR, CMKRL2, DRY12, FEG-1, GPCR-Br, GPER}, BAK1 (BCL2 antagonist/killer 1) [NCBI Gene 578] {aka BAK, BAK-LIKE, BCL2L7, CDN1}, INS (insulin) [NCBI Gene 3630] {aka IDDM, IDDM1, IDDM2, ILPR, IRDN, MODY10}, SLC25A20 (solute carrier family 25 member 20) [NCBI Gene 788] {aka CAC, CACT}, SOD1 (superoxide dismutase 1) [NCBI Gene 6647] {aka ALS, ALS1, HEL-S-44, IPOA, SOD, STAHP}, CREB1 (cAMP responsive element binding protein 1) [NCBI Gene 1385] {aka CREB, CREB-1}, SLC16A2 (solute carrier family 16 member 2) [NCBI Gene 6567] {aka AHDS, DXS128, DXS128E, MCT 7, MCT 8, MCT7}, NFE2L2 (NFE2 like bZIP transcription factor 2) [NCBI Gene 4780] {aka IMDDHH, NRF2, Nrf-2}, IFIT1 (interferon induced protein with tetratricopeptide repeats 1) [NCBI Gene 3434] {aka C56, G10P1, IFI-56, IFI-56K, IFI56, IFIT-1}, TNFSF10 (TNF superfamily member 10) [NCBI Gene 8743] {aka APO2L, Apo-2L, CD253, TANCR, TL2, TNLG6A}, CPT1A (carnitine palmitoyltransferase 1A) [NCBI Gene 1374] {aka CPT I, CPT1, CPT1-L, CPTI-L, L-CPT1}, IL6 (interleukin 6) [NCBI Gene 3569] {aka BSF-2, BSF2, CDF, HGF, HSF, IFN-beta-2}, BAX (BCL2 associated X, apoptosis regulator) [NCBI Gene 581] {aka BCL2L4}, TNF (tumor necrosis factor) [NCBI Gene 7124] {aka DIF, IMD127, TNF-alpha, TNFA, TNFSF2, TNLG1F}, IL10 (interleukin 10) [NCBI Gene 3586] {aka CSIF, GVHDS, IL-10, IL10A, TGIF}, BCL2 (BCL2 apoptosis regulator) [NCBI Gene 596] {aka Bcl-2, PPP1R50}, CGB7 (chorionic gonadotropin subunit beta 7) [NCBI Gene 94027] {aka CG-beta-a, CGB6}, PGF (placental growth factor) [NCBI Gene 5228] {aka D12S1900, PGFL, PIGF, PLGF, PlGF-2, SHGC-10760}, FLT1 (fms related receptor tyrosine kinase 1) [NCBI Gene 2321] {aka FLT, FLT-1, VEGFR-1, VEGFR1}, GPX1 (glutathione peroxidase 1) [NCBI Gene 2876] {aka GPXD, GSHPX1}, SLCO1C1 (solute carrier organic anion transporter family member 1C1) [NCBI Gene 53919] {aka OATP-F, OATP-RP5, OATP1, OATP14, OATP1C1, OATPF}, MIF (macrophage migration inhibitory factor) [NCBI Gene 4282] {aka GIF, GLIF, MMIF}, BAD (BCL2 associated agonist of cell death) [NCBI Gene 572] {aka BBC2, BCL2L8}, LEP (leptin) [NCBI Gene 3952] {aka LEPD, OB, OBS}, CASP3 (caspase 3) [NCBI Gene 836] {aka CPP32, CPP32B, SCA-1}, EGFR (epidermal growth factor receptor) [NCBI Gene 1956] {aka ERBB, ERBB1, ERRP, HER1, NISBD2, NNCIS}, LGALS3 (galectin 3) [NCBI Gene 3958] {aka CBP35, GAL3, GALBP, GALIG, L31, LGALS2}, IGF2 (insulin like growth factor 2) [NCBI Gene 3481] {aka C11orf43, GRDF, IGF-II, PP9974, SRS3}, PPARG (peroxisome proliferator activated receptor gamma) [NCBI Gene 5468] {aka CIMT1, FPLD3, GLM1, NR1C3, PPARG1, PPARG2}, CRH (corticotropin releasing hormone) [NCBI Gene 1392] {aka CRF, CRH1}, TRH (thyrotropin releasing hormone) [NCBI Gene 7200] {aka Pro-TRH, TRF}, ABCG2 (ATP binding cassette subfamily G member 2 (JR blood group)) [NCBI Gene 9429] {aka ABC15, ABCP, BCRP, BMDP, CD338, CDw338}, PFAS (phosphoribosylformylglycinamidine synthase) [NCBI Gene 5198] {aka FGAMS, FGAR-AT, FGARAT, GATD8, PURL}
- **Diseases:** immune system disturbances (MESH:D007154), placental dysfunction (MESH:D010922), endocrine disruption (MESH:D004700), reproductive failure (MESH:D051437), preterm birth (MESH:D047928), PFASs (MESH:D019966), gestational hypertension (MESH:D046110), HOMA-IR (MESH:D007333), preeclampsia (MESH:D011225), Toxicity (MESH:D064420), intrauterine growth restriction (MESH:D005317), metabolic disturbances (MESH:D024821), injury to (MESH:D014947), inflammation (MESH:D007249), growth impairment (MESH:D006130), mitochondrial damage (MESH:D028361), lipid (MESH:D011017), pregnancy loss (MESH:D000022), gestational diabetes (MESH:D016640), impaired maternal and neonatal thyroid function (MESH:D007232), type 2 diabetes (MESH:D003924), dysfunction (MESH:D006331), tumorigenesis (MESH:D063646)
- **Chemicals:** prostaglandin (MESH:D011453), NADPH (MESH:D009249), histidine (MESH:D006639), amino acids (MESH:D000596), PFHpA (MESH:C101815), leukotriene (MESH:D015289), PFUdA (MESH:C586085), PFPeA (MESH:C000619812), tricarboxylic acid (MESH:D014233), carbon (MESH:D002244), oil (MESH:D009821), fatty acid (MESH:D005227), linoleic acid (MESH:D019787), perfluorooctane sulfonamide (MESH:C063900), metal (MESH:D008670), 6:2 perfluorooctane sulfonate (-), PFBA (MESH:C033094), PFNA (MESH:C101816), PFDS (MESH:C000720114), carnitine (MESH:D002331), salt (MESH:D012492), PFOS (MESH:C076994), hydrogen (MESH:D006859), branched-chain amino acids (MESH:D000597), NADH (MESH:D009243), lysophosphatidylcholine (MESH:D008244), PFOA (MESH:C023036), folate (MESH:D005492), reactive oxygen species (MESH:D017382), ether (MESH:D004986), PFPrA (MESH:C033093), 8-hydroxy-2'-deoxyguanosine (MESH:D000080242), PFDA (MESH:C036567), glutathione (MESH:D005978), PFBS (MESH:C539348), Per- and polyfluoroalkyl substances (MESH:D005466), fluorine (MESH:D005461), HFPO-DA (MESH:C000611729), 2-hydroxybutyrate (MESH:C031570), ATP (MESH:D000255), water (MESH:D014867), PFHxA (MESH:C479228), FTS (MESH:C000720117), lipid (MESH:D008055), PFHxS (MESH:C471071), sulfonates (MESH:D000476), lysophosphatidylethanolamine (MESH:C008301)
- **Species:** Mus musculus (house mouse, species) [taxon 10090], Rattus norvegicus (brown rat, species) [taxon 10116], Homo sapiens (human, species) [taxon 9606], Danio rerio (leopard danio, species) [taxon 7955]
- **Cell lines:** JEG-3 — Homo sapiens (Human), Gestational choriocarcinoma, Cancer cell line (CVCL_0363), HTR-8/SVneo — Homo sapiens (Human), Transformed cell line (CVCL_7162), HTR-8 — Homo sapiens (Human), Finite cell line (CVCL_D728)

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12941165/full.md

## Figures

1 figure with captions in the complete paper: https://tomesphere.com/paper/PMC12941165/full.md

## References

87 references — full list in the complete paper: https://tomesphere.com/paper/PMC12941165/full.md

---
Source: https://tomesphere.com/paper/PMC12941165